Chris Boerner, Bristol Myers Squibb COO
September 15, 2023 11:29 AM EDTUpdated September 22, 04:22 AM
Pharma
Manufacturing

Bris­tol My­er­s' man­u­fac­tur­ing shut­down means low­er-than-ex­pect­ed Q3 sales for Abec­ma

Anna Brown

News Reporter

Bris­tol My­ers Squibb and 2sev­en­ty bio said this week that a man­u­fac­tur­ing shut­down will trans­late to low­er-than-ex­pect­ed sales for their CAR-T cell ther­a­py Abec­ma in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times